Treatment progress of enteropathy-associated T-cell lymphoma

VernacularTitle:肠病相关T细胞淋巴瘤的治疗新进展
Author: Xiaobing LIANG ¹ ; Jia FENG
Author Information

1. 北京大学深圳医院血液内科，深圳　518000
Keywords: Enteropathy-associated T-cell lymphoma; Immunophenotype; Hematopoietic stem cell transplantation; Therapy
From: Journal of Leukemia & Lymphoma 2025;34(10):634-637
CountryChina
Language:Chinese
Abstract: Enteropathy-associated T-cell Lymphoma (EATL) is an extranodal T-cell lymphoma originating in the intestinal tract, and the standard treatment regimen for patients with EATL has not yet been established. CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) regimen is clinically used as the first-line chemotherapy regimen for most patients, and autologous stem cell transplantation (ASCT) can be considered as the following consolidation therapy. With advancements in medical technology, emerging approaches such as novel chemotherapy regimens, immune-targeted agents, hematopoietic stem cell transplantation, and cellular immunotherapy have been developed. This review focuses on recent treatment progress of EATL.